In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future.
Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have during a session at AMCP 2023.
TSX.V: DME Frankfurt: QM01 Desert Mountain Energy Corp. From the President of the Company. The Company is pleased to announce the closing of its previously announced "best efforts" public offering of 11,300,000 units of the Company at a price of. - Veroeffentlicht am 24.03.2023